Reference : CCT196969 effectively inhibits growth and survival of melanoma brain metastasis cells |
Scientific journals : Article | |||
Life sciences : Biochemistry, biophysics & molecular biology | |||
http://hdl.handle.net/10993/54416 | |||
CCT196969 effectively inhibits growth and survival of melanoma brain metastasis cells | |
English | |
Reigstad, Agathe [University of Bergen - UiB > Department of Biomedicine] | |
Herdlevær, Christina Frantzen [University of Bergen - UiB > Department of Biomedicine] | |
Rigg, Emma [University of Bergen - UiB > Department of Biomedicine] | |
Hoang, Tuyen [University of Bergen - UiB > Department of Biomedicine] | |
Bjørnstad, Ole Vidhammer [University of Bergen - UiB > Department of Biomedicine] | |
Aasen, Synnøve Nymark [University og Bergen - UiB > Department of Biomedicine > > ; Western Norway University of Applied Sciences > Faculty of Health and Social Sciences] | |
Preis, Jasmin Renate ![]() | |
Haan, Claude ![]() | |
Sundstrøm, Terje [HaukelHaukeland University Hospital > Department of Neurosurgery > > ; University of Bergen - UiB > Department of Clinical Medicine] | |
Thorsen, Frits [University of Bergen - UiB > Department of Biomedicine > > ; University of Bergen - UiB > Department of Biomedicine > Molecular Imaging Center] | |
9-Sep-2022 | |
PLoS ONE | |
Public Library of Science | |
Yes | |
1932-6203 | |
San Franscisco | |
United States - California | |
[en] Melanomas frequently metastasize to the brain. Despite recent progress in the treatment of
melanoma brain metastasis, therapy resistance and relapse of disease remain unsolved challenges. CCT196969 is a SRC family kinase (SFK) and Raf proto-oncogene, serine/thre onine kinase (RAF) inhibitor with documented effects in primary melanoma cell lines in vitro and in vivo. Using in vitro cell line assays, we studied the effects of CCT196969 in multiple melanoma brain metastasis cell lines. The drug effectively inhibited proliferation, migration, and survival in all examined cell lines, with viability IC50 doses in the range of 0.18–2.6 μM. Western blot analysis showed decreased expression of p-ERK, p-MEK, p-STAT3 and STAT3 upon CCT196969 treatment. Furthermore, CCT196969 inhibited viability in two B Raf Proto-Oncogene (BRAF) inhibitor resistant metastatic melanoma cell lines. Further in vivo studies should be performed to determine the treatment potential of CCT196969 in patients with treatment-naïve and resistant melanoma brain metastasis. | |
http://hdl.handle.net/10993/54416 | |
10.1371/journal.pone.0273711 | |
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0273711 |
File(s) associated to this reference | ||||||||||||||
Fulltext file(s):
| ||||||||||||||
All documents in ORBilu are protected by a user license.